Brought to you by 
Celera sells cancer and autoimmune programs to Pharmacyclics
30 Jan 2023
Executive Summary
Applera's Celera Genomics division has announced its intention to restructure and focus only on molecular diagnostics and proteomics. As part of this plan, it has sold off multiple small-molecule cancer and autoimmune drug candidates to Pharmacyclics (oncology and atherosclerosis treatments).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Celera sells cancer and autoimmune programs to Pharmacyclics
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice